Results 101 to 110 of about 14,850 (194)

Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3193-3201, April 2026.
Abstract Aims To assess whether preoperative sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) use reduces the odds of postoperative acute kidney injury (AKI) in patients with type 2 diabetes undergoing surgery. Methods We conducted a target trial emulation using inverse probability of treatment weighting, utilising routinely collected data from a ...
Frank M. Gao, Kartik Kishore, Dinesh Pandey, Hossein Jahanabadi, Meg Stevens, Ashani Lecamwasam, Leonid Churilov, Elif I. Ekinci   +7 more
wiley   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3254-3263, April 2026.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone, Erik Moedt, Hiddo J. L. Heerspink, Michael J. Davies, Manon Girard, David Z. I. Cherney, Marcel H. A. Muskiet   +6 more
wiley   +1 more source

Comparative effectiveness of combination therapy with SGLT‐2 inhibitors and GLP‐1 RAs compared with SGLT‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3273-3284, April 2026.
Abstract Aims To evaluate the effectiveness of combination therapy with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) compared with continued SGLT‐2 inhibitor therapy in routine practice among individuals with type 2 diabetes.
Gregor A. Maier, Beata Hennig, Wolfgang Rathmann, Oliver Kuss   +3 more
wiley   +1 more source

The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

Journal of Internal Medicine, Volume 299, Issue 4, Page 444-466, April 2026.
Abstract Increased urinary albumin excretion is a strong predictor for cardiovascular events in persons with and without decreased glomerular filtration rate and can be assessed with the urinary albumin‐to‐creatinine ratio (UACR), which is a selective, sensitive, and convenient method for patients.
Holly J. Kramer, George L. Bakris
wiley   +1 more source

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson   +4 more
wiley   +1 more source

Pharmacoeconomics of dapagliflozin in patients with type 2 diabetes mellitus with inadequate glycemic control

Качественная клиническая практика, 2018
Objectives. To evaluate the cost-effectiveness of dapagliflozin in combination with metformin in the treatment T2DM in comparison with glimepiride and sitagliptin also combined with metformin. Methods.
S. K. Zyryanov, M. F. Kalashnikova, D. Yu., E. V. Afanasyeva   +3 more
doaj  

Renal‐Limited Thrombotic Microangiopathy due to Anti‐VEGF/TKI Immunotherapy for Metastatic Renal Cell Carcinoma Presenting as Nephrotic Syndrome: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Vascular endothelial growth factor (VEGF) inhibition may result in proteinuria, worsening hypertension, chronic kidney injury, or glomerular disease. Recently, systemic VEGF inhibition has been reported to cause nephrotic disorders and thrombotic microangiopathy (TMA).
Sundus Sardar, Ahmad Matarneh, Omar K. Salameh, Abdel‐Rauof M. Akkari, Monika Joshi, Erik Washburn, Nasrollah Ghahramani, Naman Trivedi   +7 more
wiley   +1 more source

Risk of Dementia in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus DPP‐4 Inhibitors: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
SGLT2 inhibitors were associated with a significantly lower risk of incident dementia compared with DPP‐4 inhibitors in patients with type 2 diabetes. This meta‐analysis synthesises evidence from diverse real‐world cohorts and highlights the potential neuroprotective benefits of SGLT2 inhibition beyond glycemic control.
Kiran Kumari, Anusha Bai, Fnu Geeta, Nirmal Wadhwani, Rohit Kumar, Ajay Kumar, Radhika Kumari, Lata Bai, Fnu Muskan, Fnu Kashish, Mohammed Yousafzai   +10 more
wiley   +1 more source

Letter to the Editor: Indication-Specific Cost-Effectiveness of Empagliflozin Versus Dapagliflozin: Implications for Clinical and Policy Decision-Making. [PDF]

Hosp Pharm
Belančić A.
europepmc   +1 more source

Dapagliflozin [PDF]

Drugs in R & D, 2010
openaire   +1 more source